Skip to content
Business Company News, Defence

MARCH 2025 QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

AML3D Limited (ASX:AL3) 2 mins read

KEY HIGHLIGHTS DURING THE QUARTER

AML3D is reporting quarterly operating cash flow break even as the Company continues to benefit from strong growth in the US that underpinned A$2.5m in customer receipts for the March 2025 quarter. AML3D also more than doubled investment in its US facilities and technology leadership program during the quarter, compared to the prior corresponding period (“PCP”). This US investment has established a technology centre and manufacturing hub in Ohio to access the strong growth in demand for additive manufacturing across both the US Defence and industrial manufacturing sectors. AML3D has maintained a strong cash position during the quarter of A$31.4 million to fund the Company’s next growth phase, which includes a A$12 million investment to double US manufacturing capacity and a $5 million investment to establish European operations. 

Key highlights during the quarter included:

• Successful site acceptance testing of the largest ever custom WAM system for AUSTAL USA
• Continuing investment to establish US growth platform
• CEO US site visits reveal potential for a 3x expansion of the US defence opportunity
• Prototype system to extend technology leadership via increased deposition rates underway
• Audit to confirm AS9100D standards for Aviation, Space and Defence manufacturing completed

To read the full announcement, please click here


About us:

AML3D Limited, a publicly listed technology company founded in 2014, utilises new technologies to pioneer and lead metal additive manufacturing globally. Disrupting the traditional manufacturing space, AML3D has developed and patented a Wire Additive Manufacturing (WAM®) process that metal 3D prints commercial, large-scale parts for Aerospace, Defence, Maritime, Manufacturing, Mining and Oil & Gas. AML3D provides parts contract manufacturing, from its Technology Centre in Adelaide Australia, and is the OEM of ARCEMY®, an industrial metal 3D printing system that combines IIoT and Industry 4.0 to enable manufacturers to become globally competitive.

To learn more, please visit: www.aml3d.com


Contact details:

For more information, please contact:

Sean Ebert
Managing Director
AML3D Limited
+61 8 8258 2658
[email protected]

Hamish McEwin
Chief Financial Officer
AML3D Limited
+61 8 8258 2658
[email protected]

Investor Relations
The Capital Network 
Julia Maguire
+61 2 7257 7338
[email protected]

More from this category

  • Business Company News
  • 22/05/2025
  • 12:51
Strata Community Association Australasia

Interest Rate Cuts Offer Strata Sector Opportunity to Strengthen Community Stability and Reinvestment

The recent reduction in interest rates across Australia has created new opportunities for financial relief and reinvestment in strata communities, according to the Strata…

  • Contains:
  • Business Company News, Oil Mining Resources
  • 22/05/2025
  • 11:01
Jane Morgan Management

Patriot Resources (ASX:PAT) Agreement to Acquire High-Grade Sugarloaf Copper Deposit in Zambia

22 May 2025 – Perth, Australia | Patriot Resources has entered into an agreement to acquire 100% of the high-grade Sugarloaf Copper Deposit, located in Zambia’s prolific Mumbwa Copper District. The acquisition is a production opportunity for Patriot’s expanding Zambian copper portfolio that is strategically positioned around the Kitumba process plant and smelter being developed by Sinomine. Highlights: Exploration Target of 1.6 - 2.5Mt at 2.0 - 2.5% total copper (TCu), for 32,000–62,500t of contained copper. Historic drilling includes standout intercepts such as 91.76m at 2.02% TCu, including 10.01m at 6.16% TCu. Orebody is exposed at surface and considered amenable…

  • Contains:
  • Biotechnology, Business Company News
  • 22/05/2025
  • 10:51
Jane Morgan Management

BlinkLab (ASX:BB1) Engages Leading Autism Research Centre for Main Study Phase of US Diagnostic Trial

22 May 2025 – Perth, Australia | BlinkLab Limited is commencing the main study phase of its pivotal US-based FDA 510(k) diagnostic trial for its smartphone-based autism diagnostic tool with the engagement of a major new clinical site. The Southwest Autism Research & Resource Center (SARRC), a nationally recognised leader in autism research and clinical services, has been selected as the first clinical site for this next phase for trialling BlinkLab’s autism diagnostic tool, BlinkLab Dx 1. The main study will involve the recruitment of up to 900 new participants, following the pilot phase, testing up to 100 children. Testing…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.